Print Page  |  Close Window

SEC Filings

424B5
PROTAGONIST THERAPEUTICS, INC filed this Form 424B5 on 08/07/2018
Entire Document
 

Table of Contents

 

THE OFFERING

Common Stock offered by us

  2,750,000 shares.

Common Stock to be outstanding after this offering

 

23,913,590 shares.

Use of Proceeds

 

We currently intend to use the net proceeds from this offering to fund clinical research and development of PTG-100, including to potentially re-start the Phase 2b clinical trial of PTG-100. See "Use of Proceeds" on page S-15 of this prospectus supplement.

Risk Factors

 

You should carefully read and consider the information beginning on page S-9 of this prospectus supplement and page 7 of the accompanying prospectus set forth under the headings "Risk Factors" and all other information set forth in this prospectus supplement, the accompanying prospectus, and the documents incorporated herein and therein by reference before deciding to invest in our common stock and warrants.

The Nasdaq Global Market Symbol

 

Our shares are listed on The Nasdaq Global Market under the symbol "PTGX."

        The number of shares of our common stock to be outstanding after this offering is based on 21,163,590 shares of our common stock outstanding as of March 31, 2018 and excludes:

    2,984,522 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2018, having weighted average exercise price of $12.67 per share;

    an aggregate of 664,068 shares of common stock, subject to increase on an annual basis, reserved for future issuance under our 2016 Equity Incentive Plan as of March 31, 2018;

    113,625 shares issuable upon vesting of outstanding restricted stock units, or RSUs; and

    454,660 shares of our common stock, subject to increase on an annual basis, reserved for future issuance under our 2016 Employee Stock Purchase Plan, as of March 31, 2018.

        Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options or warrants after March 31, 2018.

S-8